secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-07-16T21:15:34+00:00
Accession:  0001213900-26-078781
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics completes all-stock acquisition of Kira Pharmaceuticals and $132M PIPE
--------------------------------------------------------------------------------

- Jasper acquires Kira in all-stock deal; pre-deal Jasper holders own ~6.68%, Kira holders ~49.86%, PIPE investors ~43.46% of combined company.
- Concurrent $132M private placement co-led by Affinity Asset Advisors and Ikarian Capital; expected to close July 20, 2026.
- Kira out-licenses KP-301 and KP-402 to Mirador Therapeutics for $12M upfront plus potential milestones.
- Combined company cash runway through H2 2028; key milestones include KP-104 Phase 2 renal data in Q4 2026 and end-of-Phase 2 FDA meeting for PNH in H1 2027.
- Briquilimab pre-BLA meeting for SCID expected in Q1 2027; KP-701 IND/CTA filing in Q1 2027 with first-in-human data in Q3 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026078781/0001213900-26-078781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026078781/ea0298316-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-078781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer